Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
VEGF (Vascular Endothelial Growth Factor) Antibody - With BSA and Azide
Mouse Monoclonal Antibody [Clone SPM225 ]
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| IHC, IF |
|---|---|
| Primary Accession | P15692 |
| Other Accession | 7422, 73793 |
| Reactivity | Human, Mouse, Rat, Rabbit, Dog |
| Host | Mouse |
| Clonality | Monoclonal |
| Isotype | Mouse / IgG1, kappa |
| Clone Names | SPM225 |
| Calculated MW | 19-22kDa (reducing) and 38kDa-44kDa (non-reducing) |
| Gene ID | 7422 |
|---|---|
| Other Names | Vascular endothelial growth factor A, VEGF-A, Vascular permeability factor, VPF, VEGFA, VEGF |
| Storage | Store at 2 to 8°C.Antibody is stable for 24 months. |
| Precautions | VEGF (Vascular Endothelial Growth Factor) Antibody - With BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | VEGFA |
|---|---|
| Synonyms | VEGF |
| Function | [N-VEGF]: Participates in the induction of key genes involved in the response to hypoxia and in the induction of angiogenesis such as HIF1A (PubMed:35455969). Involved in protecting cells from hypoxia- mediated cell death (By similarity). |
| Cellular Location | [N-VEGF]: Cytoplasm. Nucleus. Note=Cytoplasmic in normoxic conditions and localizes to the nucleus under hypoxic conditions [Isoform L-VEGF189]: Endoplasmic reticulum. Golgi apparatus. Secreted, extracellular space, extracellular matrix [Isoform VEGF165]: Secreted |
| Tissue Location | Higher expression in pituitary tumors than the pituitary gland. [Isoform VEGF165]: Widely expressed. [Isoform VEGF206]: Not widely expressed. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This MAb recognizes proteins of 19-22kDa (reducing) and 38kDa-44kDa (non-reducing), identified as various isoforms of Vascular Endothelial Growth Factor or Vascular Permeability Factor (VEGF/VPF). It is highly specific to VEGF, which is a homodimeric, disulfide-linked glycoprotein with a close homology to platelet derived growth factor (PDGF). There are multiple isoforms of VEGF containing 206-, 189-, 165-, and 121-amino acid residues. The smaller two isoforms, VEGF165 and VEGF121, are secreted proteins and act as diffusible agents, whereas the larger two remain cell associated. VEGF/VPF plays an important role in angiogenesis, which promotes tumor progression and metastasis.
References
Tischer, E., et al. 1991. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 266: 11947-11954. | Berse, B., et al. 1992. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages and tumors. Mol. Biol. Cell 3: 211-220. | Folkman, J., et al. 1989. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339: 58-61. |
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
